Bhanu Piyush, Godwin Andrew K, Umar Shahid, Mahoney Diane E
Bioengineering Program, School of Engineering, University of Kansas, Lawrence, KS 66045, USA.
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Cancers (Basel). 2025 May 26;17(11):1774. doi: 10.3390/cancers17111774.
Bacterial extracellular vesicles (BEVs) have emerged as pivotal mediators of host-microbe interactions, profoundly influencing cancer biology. These nanoscale vesicles, produced by both Gram-positive and Gram-negative bacteria, carry diverse biomolecular cargo such as proteins, lipids, nucleic acids, and metabolites. BEVs play dualistic roles in tumor promotion and suppression by modulating the tumor microenvironment, immune responses, and genetic regulation. This review synthesizes the current understanding of BEVs in various cancers, including gastrointestinal, ovarian, breast, lung, brain, and renal malignancies. BEVs are highlighted for their potential as diagnostic biomarkers, prognostic indicators, and therapeutic agents, including their applications in immunotherapy and advanced engineering for precision medicine. Challenges such as heterogeneity, standardization, and clinical scalability are critically analyzed, with case examples providing actionable insights. Future directions emphasize interdisciplinary collaborations, emerging technologies, and the integration of BEV-based tools into clinical workflows. This review underscores the transformative potential of BEVs in advancing cancer diagnostics and therapeutics, paving the way for innovations in precision oncology.
细菌细胞外囊泡(BEVs)已成为宿主与微生物相互作用的关键介质,对癌症生物学产生深远影响。这些纳米级囊泡由革兰氏阳性菌和革兰氏阴性菌产生,携带多种生物分子货物,如蛋白质、脂质、核酸和代谢物。BEVs通过调节肿瘤微环境、免疫反应和基因调控,在肿瘤促进和抑制中发挥双重作用。本综述综合了目前对BEVs在各种癌症中的理解,包括胃肠道、卵巢、乳腺、肺、脑和肾脏恶性肿瘤。BEVs因其作为诊断生物标志物、预后指标和治疗剂的潜力而受到关注,包括它们在免疫治疗和精准医学先进工程中的应用。对异质性、标准化和临床可扩展性等挑战进行了批判性分析,并通过案例提供了可行的见解。未来的方向强调跨学科合作、新兴技术以及将基于BEV的工具整合到临床工作流程中。本综述强调了BEVs在推进癌症诊断和治疗方面的变革潜力,为精准肿瘤学的创新铺平了道路。